Page 16 - Nsclc News Today

An overview of data presented at ESMO 2023 on the LIBRETTO-431 trial of selpercatinib in RET+ NSCLC.

Benjamin Solomon, MBBS, PhD, FRACP, presents key data from the ALINA study investigating alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).

The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.

A comprehensive study exploring NSCLC subgroup responses to immunotherapy may help determine which patients are less likely to benefit from these agents.

Robert A. Anders, MD, PhD, discusses the rationale for investigating the use of tivumecirnon in patients with non–small cell lung cancer, as well as interim data from the dose-expansion portion of the phase 1/2 FLX475-02 study of this agent alone and in combination with pembrolizumab.

China’s National Medical Products Administration has granted conditional marketing approval to vebreltinib (APL-101; PBL-1001) for the treatment of patients with non–small cell lung cancer harboring MET exon 14 skipping mutations

Experts offer concluding insights on unmet needs in NSCLC treatment and the future of patient care.

Specialists discuss unmet needs that continue to exist in treating patients with NSCLC despite advances in treatment, and how these impact patient outcomes.

The next-generation tyrosine kinase inhibitor provides a new treatment option for patients with this difficult-to-treat form of lung cancer.

A panel of thoracic medical oncologists provide an overview of first-line treatment strategies for advanced non–small cell lung cancer (NSCLC).